Tilray Brands, Inc. (TLRY) research
Tilray Brands, Inc.- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $3.61
- As of
Tilray Brands, Inc. (TLRY): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for TLRY. Method and limitations.
Share the TLRY intelligence card
See the full TLRY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TLRY on one page. Preview it with sample data, then open it live with a free account.
Preview the TLRY dossierActive signals for TLRY
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in TLRY
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 68% of TLRY (2026Q2)
- lowEARNINGS_MISS
Q4-2026: EPS $-0.43 vs $-0.0136 estimate, -0.42 on a near-zero consensus
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +72% to TLRY (2026Q1)
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 5362.2% - EPS $-13 vs $-0.238 estimate
FREE, NO ACCOUNT
Every signal on TLRY, as it fires
You are seeing 5 of 10 signals recorded on TLRY since 2026-05-29.
The five above landed across 4 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TLRY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 88688T209 · 2026Q2 | $3.9M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 88688T209 · 2026Q2 | $2.9M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 88688TAC4 · 2026Q2 | $2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 88688T209 · 2026Q2 | $666K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 88688T209 · 2026Q2 | $610K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 88688T209 · 2026Q2 | $140K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TLRY
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TLRY against its peers
TLRY's operating margin of -6.9% ranks in the 45th percentile of 18 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | TLRY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 915M USD | 236M USD | 92 | 17 |
| Gross margin | 28.4% | 49.5% | 11 | 13 |
| Operating margin | -6.9% | -2.7% | 45 | 18 |
| Net margin | -13.3% | -18.0% | 55 | 18 |
| Return on equity | -7.5% | -22.2% | 72 | 15 |
Peers (20): AQST, VREOF, EOLS, TKNO, KMDA, VRNO, NIKA, CGC, ELTP, HROW, AKBA, CRON, CRLBF, DERM, CRDL, ETON, GTBIF, TSNDF, ALVO, ADCT. Left out: EVO (period gap), BORAY (no annual filing), LFCR (no annual filing), PHBI (period gap), ASRT (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (TLRY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TLRY signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TLRYand get the insider, 13F, options, and confluence read in one view.